Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...
Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside ...
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...